Overview Financials News + Filings Key Docs Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Consulting agrmnt
|
|
Shuttle Pharmaceuticals Holdings, Inc.
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 10/10/2023 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
| 10/05/2023 |
8-K
| Entered into consulting agreement |
| 08/15/2023 |
8-K
| Results of Operations and Financial Condition, Financial Statements and Exhibits Interactive Data |
| 08/03/2023 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
| 05/26/2023 |
8-K
| Results of Operations and Financial Condition, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard... |
| 05/17/2023 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
| 05/11/2023 |
8-K
| Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits Interactive Data |
| 03/22/2023 |
8-K
| Quarterly results |
| 03/09/2023 |
8-K
| Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits Interactive Data |
| 02/22/2023 |
8-K
| Quarterly results |
| 01/26/2023 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
| 01/12/2023 |
8-K
| Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Other Events, Financial Statements and E...|
Docs:
|
"SUBSIDIARY GUARANTY FORM OF WARRANT",
"FORM OF SENIOR SECURED CONVERTIBLE NOTE NEITHER THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS NOTE NOR THE SECURITIES INTO WHICH THIS NOTE IS CONVERTIBLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT FOR THE SECURITIES UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR AN OPINION OF COUNSEL TO THE HOLDER , IN A FORM REASONABLY ACCEPTABLE TO THE COMPANY, THAT REGISTRATION IS NOT REQUIRED UNDER SAID ACT OR UNLESS SOLD OR ELIGIBLE TO BE SOLD PURSUANT TO RULE 144 UNDER SAID ACT. NOTWITHSTANDING THE FOREGOING, THE SECURITIES MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT OR OTHER LOAN O...",
"FORM OF WARRANT NEITHER THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS WARRANT NOR THE SECURITIES INTO WHICH THIS WARRANT IS EXERCISABLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT FOR THE SECURITIES UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR AN OPINION OF COUNSEL TO THE HOLDER , IN A FORM REASONABLY ACCEPTABLE TO THE COMPANY, THAT REGISTRATION IS NOT REQUIRED UNDER SAID ACT OR UNLESS SOLD OR ELIGIBLE TO BE SOLD PURSUANT TO RULE 144 OR RULE 144A UNDER SAID ACT. NOTWITHSTANDING THE FOREGOING, THE SECURITIES MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT OR OTHER LOAN OR FIN...",
"FORM OF SECURITY AGREEMENT This SECURITY AGREEMENT, dated as of January 11, 2023 , is by and among Shuttle Pharmaceuticals Holdings, Inc., a Delaware corporation , the Subsidiary Guarantors from time to time party hereto , the holders of the Company’ s Senior Secured Notes, in the original aggregate principal amount of $4,300,000.00 that are signatories hereto , and Alto Opportunity Master Fund, SPC- Segregated Portfolio B, in its capacity as agent for the Purchasers . W I T N E S S E T H: WHEREAS, pursuant to that certain Securities Purchase Agreement dated as of the date hereof, by and among the Company and the Purchasers , the Purchasers have, subject to the terms and conditions of the Purchase Agreement, severally agreed to purchase from the Company the Notes at one or more closings un...",
"FORM OF INTELLECTUAL PROPERTY SECURITY AGREEMENT This Intellectual Property Security Agreement is entered into as of January 11, 2023, by and among SHUTTLE PHARMACEUTICALS HOLDINGS INC., a Delaware corporation , the Subsidiary Guarantors from time to time party hereto , the holders of the Company’ s Senior Secured Notes, in the original aggregate principal amount of $4,300,000.00 that are signatories hereto , and Alto Opportunity Master Fund, SPC- Segregated Portfolio B in its capacity as collateral agent for the Purchasers . RECITALS A. Pursuant to that certain Securities Purchase Agreement dated as of the date hereof, by and among the Company and the Purchasers , the Purchasers have, subject to the terms and conditions of the Purchase Agreement, severally agreed to purchase from the Comp...",
"Agreement”), dated as of January 11, 2023, is made by and among each of the undersigned Guarantors and Alto Opportunity Master Fund, SPC – Segregated Master Portfolio B, as agent for the Holders .",
"NOTICE The undersigned beneficial owner of Registrable Securities hereby elects to include the Registrable Securities owned by it in the Registration Statement. The undersigned hereby provides the following information to the Company and represents and warrants that such information is accurate: QUESTIONNAIRE 1. Name. Full Legal Name of Selling Stockholder: Full Legal Name of Registered Holder above) through which Registrable Securities are held: Full Legal Name of Natural Control Person : 2. Address for Notices to Selling Stockholder: Telephone: ______________________________________ Fax: ____________________________________________ Contact Person: ___________________________________ 3. Broker-Dealer Status: Are you a broker-dealer? Yes ☐ No ☐ 2 If “yes” to Section 3 , did you...",
"Shuttle Pharmaceuticals Announces Private Placement of $4.3 Million of Senior Secured Convertible Note and Warrants ROCKVILLE, Md., Jan. 12, 2023 /PRNewswire/ — Shuttle Pharmaceuticals Holdings, Inc. , a discovery and development stage specialty pharmaceutical company focused on improving the outcomes of cancer patients treated with radiation therapy while reducing side effects, announced the issuance of a $4.3 million senior secured convertible note and warrant to an institutional investor. Shuttle Pharmaceuticals will receive initial gross proceeds of $4.0 million. In addition, the four-year warrant to purchase up to approximately 1.018 million shares of Shuttle Pharmaceuticals’ common stock at an exercise price of $2.35 per share, upon exercise, would result in additional proceeds of ap..." |
|
| 12/19/2022 |
8-K
| Submission of Matters to a Vote of Security Holders Interactive Data |
| 12/07/2022 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits Interactive Data |
| 11/01/2022 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 09/22/2022 |
8-K
| Entry into a Material Definitive Agreement |
| 09/19/2022 |
8-K
| Entry into a Material Definitive Agreement, Financial Statements and Exhibits |
| 09/06/2022 |
8-K
| Entry into a Material Definitive Agreement, Financial Statements and Exhibits|
Docs:
|
"Shuttle Pharmaceuticals Announces Closing of Initial Public Offering ROCKVILLE, Maryland – September 6, 2022 — Shuttle Pharmaceuticals Holdings, Inc. , a discovery and development stage specialty pharmaceutical company focused on improving the outcomes of cancer patients treated with radiation therapy while reducing side effects, today announced the closing of its initial public offering of 1,225,888 units of common stock and warrants at a public offering price of $8.125 per unit, for aggregate proceeds of $9,960,340, before deducting underwriting discounts and estimated offering expenses. Each unit consisted of one share of common stock and a warrant to purchase one share of common stock. Each of the warrants were exercised simultaneously with closing at an exercise price of $0.01 per sha..." |
|
|
|